Maloney Shawn C, Fernandes Bruno F, Penteado Rafaella Cleto, Antecka Emilia, Bravo-Filho Vasco, Sanft Debra Meghan, Burnier Miguel N
The Henry C. Witelson Ocular Pathology Laboratory, McGill University, 3775 University Street, Room 216, Montreal, QC, Canada H3A 2B4.
J Ophthalmol. 2013;2013:683963. doi: 10.1155/2013/683963. Epub 2013 Aug 1.
Introduction. Uveal melanoma (UM) is an intraocular tumor that leads to metastatic disease in approximately 50% of afflicted patients. There is no efficacious treatment for metastatic disease in this cancer. Identification of markers that can offer prognostic and therapeutic value is a major focus in this field at present. KAI1 is a metastasis suppressor gene that has been reported to play a role in various human malignancies, although it has not previously been evaluated in UM. Purpose. To investigate the expression of KAI1 in UM and its potential value as a prognostic marker. Materials and Methods. 18 cases of human primary UM were collected and immunostained for KAI1 expression. A pathologist evaluated staining intensity and distribution semiquantitatively. Each case was categorized as group 1 (low staining) or group 2 (high staining). Results. In group 2, two of the 12 cases presented with metastasis. Conversely, in group 1, five out of 6 cases had metastasis. The mean follow-up of patients who did not develop metastasis was 81.81 months (median: 75 months) versus 42.14 months (median: 44 months) for patients with metastasis. Conclusions. KAI1 is a promising candidate marker that may offer prognostic value in UM; it may also represent a therapeutic target in metastatic disease.
引言。葡萄膜黑色素瘤(UM)是一种眼内肿瘤,约50%的患病患者会发生转移性疾病。对于这种癌症的转移性疾病,目前尚无有效的治疗方法。识别具有预后和治疗价值的标志物是该领域目前的主要研究重点。KAI1是一种转移抑制基因,已报道其在多种人类恶性肿瘤中发挥作用,尽管此前尚未在UM中进行评估。目的。研究KAI1在UM中的表达及其作为预后标志物的潜在价值。材料与方法。收集18例人类原发性UM病例,对KAI1表达进行免疫染色。一名病理学家对染色强度和分布进行半定量评估。每个病例分为1组(低染色)或2组(高染色)。结果。在2组中,12例中有2例出现转移。相反,在1组中,6例中有5例发生转移。未发生转移患者的平均随访时间为81.81个月(中位数:75个月),而发生转移患者的平均随访时间为42.14个月(中位数:44个月)。结论。KAI1是一个有前景的候选标志物,可能在UM中具有预后价值;它也可能代表转移性疾病的一个治疗靶点。